9 research outputs found
Additional file 7 of Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Additional file 7. Supplementary Table 4A-D: Oncotype models
Additional file 6 of Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Additional file 6. Supplementary Table 3: Demographics of Combined Training and Validation Oncotype Dataset
Additional file 1 of Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Additional file 1. Methods
Additional file 2 of Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Additional file 2. Supplementary Table 1: PDxBr Training and Validation: Clinical Feature only model
Additional file 4 of Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Additional file 4. Supplementary Figure 1: MindAct Clinical Risk Models vs. PDxBr in training (A) vs validation (B)
Additional file 5 of Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Additional file 5.. Supplementary Figure 2: Kaplan-Meier Comparison of Histologic Grade vs. AI-grade in Full Train and Validation Cohort
Additional file 8 of Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Additional file 8. Supplemental Figure 3: AUC/C-index Oncotype Models
Additional file 3 of Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years
Additional file 3. Supplementary Table 2: PDxBr Training and Validation: Image Feature Only Model
